Pipeline

Pipeline

The Potential to
Transform Treatment

Anokion is on the leading edge of harnessing the body’s natural immune tolerance pathway to address significant unmet medical need. Our innovative platform has the potential to treat multiple autoimmune diseases with therapies that deliver substantial clinical benefit without the untoward side effects associated with the current standard of care. Our goal is to discover, develop and deliver transformative therapies by directly and specifically modulating the patient’s own disease-associated T cells.

Discovery
IND-Enabling
Phase 1
Phase 2
Celiac Disease

KAN-101

KAN-101
 
Multiple Sclerosis

ANK-700

ANK-700
 
Type 1 Diabetes

KAN-201

KAN-201
 
Undisclosed


 

Expanded Access Policy

Anokion SA (including our wholly owned subsidiaries Anokion US, Inc. and Kanyos Bio, Inc.) is focused on improving the lives of individuals with autoimmune disease. The company is currently developing KAN-101 for the treatment of celiac disease. KAN-101 is an experimental therapy in early clinical development. Anokion is focused on enrolling and conducting KAN-101 clinical trials with the aim of gaining appropriate regulatory approvals to enable this therapy being available to individuals with celiac disease.

At this stage of early development, Anokion does not currently offer an Expanded Access Program for KAN-101 but the company recognizes the need for such programs and will re-evaluate our policy as we continue to advance development of the product candidate. However, the company believes that participation in a KAN-101 clinical trial is the most appropriate way to access KAN-101. Information regarding our ongoing KAN-101 trials can be found at clinicaltrials.gov.